Drugs / hAd5-S-Fusion+N-ETSD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04845191 | Dec 2021 | COVID-19 | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hAd5-S-Fusion+N-ETSD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04845191 ↗ |
| Modality | Vaccine | “targeted COVID-19 Vaccine to Enhance T Cell Based Immunogenicity” NCT04845191 ↗ |
| Route | Oral | “formulated for subcutaneous and oral (capsule) administration.” NCT04845191 ↗ |
| Route | Subcutaneous | “formulated for subcutaneous and oral (capsule) administration.” NCT04845191 ↗ |